Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by cra1gBon Mar 01, 2021 8:09am

204 Views

Post# 32683783

Level 2 is looking good

$0.07	2130000	73	$0.07	1610000	30
$0.065	354000	20	$0.075	273000	8
$0.06	614000	20	$0.08	895000	10
$0.055	408000	12	$0.085	202000	5
$0.05	1236000	16	$0.09	331000	11
$0.045	729000	10	$0.095	906000	12
$0.04	1517000	24	$0.10	2731000	30
$0.035	327000	12	$0.105	42000	4
$0.03	1739000	30	$0.11	840000	12
$0.025	309000	12	$0.115	105000	2